By Diana Bruk Published May 1, 2025, 3:10 p.m. A county in southern Texas, near the US-Mexico border, is suffering from a bit of an epidemic. Starr County has emerged as a national hot spot — not for tourism or industry, but for having one of the highest rates of dementia in the country. Roughly one in five seniors […]
iLoF, the leading innovator in AI-powered photonics platforms for personalised medicine, announces today a strategic investment from Hamamatsu, the world expert in the development and manufacturing of photonics devices and systems for medical optics and biophotonics, to further its mission of transforming healthcare and driving innovation in medicine. LONDON, Oct. 22, 2024 /PRNewswire/ — iLoF, the leading company […]
*”This story reposted in its entirely in the original posted language”*En un evento celebrado en la Conferencia de Optimización de Sitios GAP-Net 2025 en Miami, Florida, la Global Alzheimer’s Platform Foundation® reconoció a Dilenia Cruz como una de las figuras clave en la lucha contra enfermedades neurodegenerativas al otorgarle el prestigioso título de Citizen Scientist Cultivator […]
Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition Washington D.C., Mar. 27, 2025 – International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the Alzheimer’s Disease Data Initiative proudly announced four winners of the Bio-Hermes Biomarker Data Challenge at the first Data […]
The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research working with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) proudly announces the first-of-its-kind Data Challenge Summit which will unveil the results stemming from the Bio-Hermes-001 Biomarker Data Challenge. The research competition was launched in February of 2024 to allow researchers early access […]
John Peters said the clinical trial he participated in at the Kawartha Centre gave him parts of his life back. John Peters wasn’t surprised when he started having trouble remembering things — he knew both his father and grandfather battled with Alzheimer’s. “The only big difference was I never smoked,” said Peters. “I was not […]
By Allie Corey Published March 11, 2025 6:01pm EDT FOX 13 News Ironman athlete with Alzheimer’s sets a new goal FOX 13’s Allie Corey highlights Scott Berkheiser, who is inspiring others by competing in the Ironman Triathlon despite being diagnosed with early-onset Alzheimer’s at 55 years old. The Brief TAMPA, Fla. – The Ironman Triathlon is a grueling […]
International non-profit expands research network to Syracuse to improvecommunity access to research opportunities Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, […]
The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]
Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]
Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]
Ralph Kern, MD, MHSc, CMO of Cognito Therapeutics, discusses scaling up clinical trials, integrating patient centricity and transitioning from therapeutics to device treatments. February 13, 2025 Tell us about the scientific foundation behind the Spectris ADTM device. Our non-invasive investigational Spectris ADTM device evokes 40 Hz brain gamma oscillations through audiovisual stimulation. It’s delivered in […]
Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying to answer that question. Neuropsychologist Dr. Michelle Papka, the trial’s principal investigator and founder of the CRCNJ, explains the science. Researchers and technology companies are investigating whether non-invasive electromagnetic, visual, and […]
The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum of understanding, the consortium, led by scholars from Harvard University, will gain early access to Bio-Hermes-001 data to investigate the potential for […]
January 30, 2025 10:24 PM in News – Local By: Lily Celeste The Rio Grande Valley has one of the highest rates of Alzheimer’s in the country, and a clinic in Rio Grande city is attempting to find out why. Dina Ximenez said she’s been volunteering for three years for Alzheimer’s studies conducted by El Faro Health Clinic […]
Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]
By Anjelica Rubin – Technology/Tampa Bay Inno reporter, Tampa Bay Business Journal Jan 27, 2025 Updated Jan 28, 2025 5:39pm EST Just over one year after being acquired to help build a clinical research center, Tampa-based Axiom Brain Health celebrated the next chapter in its neurodegenerative research at the launch of its new site on Jan. 23. The expansion […]
Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]
Tampa, Fla. Jan. 24, 2025—Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening […]
By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]
Some turn to clinical trials to access breakthrough drugs By Cindy Krischer Goodman | cgoodman@sunsentinel.com | South Florida Sun Sentinel UPDATED: December 11, 2024 at 8:00 AM EST The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live normally, but accessing them in Florida is complicated. Hold-ups related to insurance […]
The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]
Citizen Scientists Suzanne and Mike O’Brien of #GAPNet site JEM Research Institute
ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]